A complete oral regimen for induction therapy of patients with high‐risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy

Summary There is an urgent need for an oral, efficient and safe regimen for high‐risk APL under the pandemic of COVID‐19. We retrospectively analysed 60 high‐risk APL patients. For induction therapy (IT), in addition to all‐trans retinoic acid (ATRA) and oral arsenic (RIF), 22 patients received oral...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2024-08, Vol.205 (2), p.510-516
Hauptverfasser:	Tang, Fei‐Fei, Duan, Wen‐Bing, Liu, Xiao‐Hong, Lu, Sheng‐Ye, Zhao, Xiao‐Su, Qin, Ya‐Zhen, Jia, Jin‐Song, Wang, Jing, Gong, Li‐Zhong, Jiang, Qian, Zhao, Ting, Shi, Hong‐Xia, Chang, Ying‐Jun, Huang, Xiao‐Jun, Jiang, Hao
Format:	Artikel
Sprache:	eng
Schlagworte:	acute promyelocytic leukaemia Administration, Oral Adult Aged Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Arsenic Arsenic - administration & dosage Chemotherapy completely oral COVID-19 Cytotoxicity Etoposide Etoposide - administration & dosage Etoposide - therapeutic use Female Humans Induction Chemotherapy - methods Induction therapy Infusions, Intravenous Intravenous administration Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - mortality Male Middle Aged Remission Remission Induction Retinoic acid Retrospective Studies SARS-CoV-2 Survival Tretinoin - administration & dosage Tretinoin - therapeutic use VP16 protein
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!